Brought to you by 
Oxford Glyco, Ludwig Institute map breast cancer proteome
02 Mar 2004
Executive Summary
Oxford GlycoSciences (studying proteomics, the link among genes, proteins, and physiological processes) and the Ludwig Institute for Cancer Research are allying to make a systematic study of the protein expression implicated in breast cancer.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Oxford Glyco, Ludwig Institute map breast cancer proteome
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice